Search Tisotumab vedotin Explore Ongoing Studies See How It Works Tisotumab vedotin is designed to target tissue factor (TF) using our proprietary antibody–drug conjugate (ADC) technology. TF is highly expressed on many solid tumors, including ovarian, prostate, bladder, esophageal, endometrial, and lung tumors.1,2,3 Tisotumab vedotin is being developed in collaboration with Genmab. Proposed mechanism of action References + Patients and Caregivers Diseases We Study Real Stories Clinical Trials Support and Resources Healthcare Professionals Medical Information Clinical Data Requests Investigator-Sponsored Research Medical Education Grants Site Map Contact Us FAQs Sign up for updates This website is intended for U.S. residents only. ©2021 Seagen Inc. Privacy Policy Terms and Conditions Social Media Terms > Cookie Notification By continuing to browse the site, you agree to accept our use of cookies. For more information, please review our Cookies Policy. Accept